FLT3-ITD microclones in AML and Results from the RESET-PV trial

In this week's episode, *Blood* editor Dr. Laura Michaelis interviews Drs. Pierre-Yves Dumas and Samik Basu on their latest articles published in *Blood*. Dr. Dumas talks about "Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy" where the team was able to identify e that ultra-low-burden FLT3-ITD microclones are associated with higher relapse risk and inferior relapse-free survival. Their work encourages the evaluation of FLT3 inhibitor strategies. Dr. Basu discusses "CD19 CAR T-cell therapy is feasible for patients with pemphigus vulgaris treated without lymphodepletion in the RESET-PV trial". In four patients, the treatment was well tolerated and supported CAR T-cell expansion and persistence, challenging the need for lymphodepletion and supporting chemotherapy-free approaches in autoimmune disease.